Detail akcie NewAmst Ph Co Rg online

Business Summary: NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, NewAmsterdam Pharma Company NV revenues decreased 31% to $22.5M. Net loss decreased 14% to $128.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects R&D decrease of 29% to $64.1M (expense), Foreign Exchange Gain/LossNon-Business increase from $1.3M to $13.1M (income).